TW200942549A - Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 - Google Patents

Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1

Info

Publication number
TW200942549A
TW200942549A TW097148847A TW97148847A TW200942549A TW 200942549 A TW200942549 A TW 200942549A TW 097148847 A TW097148847 A TW 097148847A TW 97148847 A TW97148847 A TW 97148847A TW 200942549 A TW200942549 A TW 200942549A
Authority
TW
Taiwan
Prior art keywords
imidazolo
oxazolo
trpv1
thiazolopyrimidine
modulators
Prior art date
Application number
TW097148847A
Other languages
English (en)
Inventor
Bryan James Branstetter
James Guy Breitenbucher
Alec D Lebsack
Jing Liu
Jason C Rech
Wei Xiao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200942549A publication Critical patent/TW200942549A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW097148847A 2007-12-17 2008-12-16 Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 TW200942549A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1415807P 2007-12-17 2007-12-17

Publications (1)

Publication Number Publication Date
TW200942549A true TW200942549A (en) 2009-10-16

Family

ID=40754075

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097148847A TW200942549A (en) 2007-12-17 2008-12-16 Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1

Country Status (10)

Country Link
US (4) US8288397B2 (zh)
EP (1) EP2224929B1 (zh)
JP (1) JP5562865B2 (zh)
AR (1) AR069777A1 (zh)
CL (1) CL2008003749A1 (zh)
PA (1) PA8808201A1 (zh)
PE (1) PE20091102A1 (zh)
TW (1) TW200942549A (zh)
UY (1) UY31540A1 (zh)
WO (1) WO2009078999A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
JP6081797B2 (ja) * 2009-07-07 2017-02-15 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ （２，４−ジメチルビフェニル−３−イル）酢酸、それらのエステルおよび中間体を調製する方法
WO2011078143A1 (ja) * 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2012078909A1 (en) * 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Thiazolpyrimidine proteostasis regulators
CA2873975A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Thienopyrimidines
JP2016512491A (ja) * 2013-03-06 2016-04-28 バイエル・ファルマ・アクティエンゲゼルシャフト 置換チアゾロピリミジン類
RU2016110852A (ru) 2013-09-27 2017-10-30 Нимбус Айрис, Инк. Ингибиторы irak и их применения
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
IT201600070952A1 (it) * 2016-07-07 2018-01-07 Univ Degli Studi Di Ferrara NUOVI TIAZOLO[5,4-d]PIRIMIDIN DERIVATI QUALI AGONISTI INVERSI DEI RECETTORI A2A DELL’ADENOSINA
CA3106692A1 (en) * 2017-07-19 2019-01-24 Aazeintx Inc. Method to abate acute airway hypersensitivity and asthma attacks
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
WO2021102330A1 (en) * 2019-11-21 2021-05-27 Synventa Llc Compositions and methods for treatment of pain

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160834A (en) 1977-03-09 1979-07-10 Eli Lilly And Company 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
JPH03167178A (ja) 1989-11-24 1991-07-19 Taiji Nakayama ピリミジン誘導体
JPH03255077A (ja) 1990-03-01 1991-11-13 Taiji Nakayama ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
SE468719B (sv) 1991-07-02 1993-03-08 Saab Scania Ab Arrangemang foer braensleledning vid foerbraenningsmotor
AU3427093A (en) 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH06172355A (ja) 1992-04-14 1994-06-21 Mect Corp ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
JPH0625243A (ja) 1992-07-08 1994-02-01 Sankyo Co Ltd １−メチルカルバペネム誘導体の製造法
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19624069A1 (de) 1996-06-17 1997-12-18 Thomae Gmbh Dr K Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6150343A (en) 1993-06-30 2000-11-21 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5834461A (en) 1993-07-29 1998-11-10 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US5985799A (en) 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
AU3296497A (en) 1996-06-13 1998-01-07 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
AU7445498A (en) 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP2001097979A (ja) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP2001294572A (ja) 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
AP2001002196A0 (en) 2000-06-28 2002-12-21 Pfizer Prod Inc Melanocortin receptor ligands.
EP1181933A3 (en) 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
IL143942A0 (en) 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
ATE302751T1 (de) 2000-06-30 2005-09-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit
US6369222B1 (en) 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03002294A (es) 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EP1192943A3 (en) 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
EP1345922B1 (en) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP2256104A1 (en) 2000-12-27 2010-12-01 Merck Patent GmbH Process for the preparation of alpha-aminosubstituted carboxylic acid amides
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
EP2336133A1 (en) * 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
EP1448565B1 (en) 2001-11-30 2009-12-30 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
CN1627944A (zh) 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
US20030199514A1 (en) 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
EP1552842A1 (en) 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
JP2005535631A (ja) * 2002-06-27 2005-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー プリン誘導体の合成
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
US20040157645A1 (en) * 2003-02-12 2004-08-12 Smith Adrian David System and method of operation an array antenna in a distributed wireless communication network
AR045979A1 (es) * 2003-04-28 2005-11-23 Astrazeneca Ab Amidas heterociclicas
WO2004108120A1 (en) 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
DE602004023299D1 (de) 2003-07-21 2009-11-05 Pfizer Prod Inc Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen
KR20060118398A (ko) 2003-08-05 2006-11-23 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물
WO2005014548A1 (ja) 2003-08-08 2005-02-17 Sumitomo Chemical Company, Limited ジソピラミド遊離塩基の低融点型結晶の製造方法
US20070105865A1 (en) 2003-09-09 2007-05-10 Neurogen Corporation Substituted bicyclic quinazolin-4-ylamine derivatives
CA2540640A1 (en) 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2007507494A (ja) * 2003-10-07 2007-03-29 アストラゼネカ・アクチエボラーグ ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン
CA2545725A1 (en) 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
US7816356B2 (en) 2003-11-14 2010-10-19 Daniel Yohannes Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
JP2005162673A (ja) 2003-12-03 2005-06-23 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
MXPA06008257A (es) 2004-01-23 2006-08-31 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
EP1731523A4 (en) 2004-04-01 2009-08-12 Takeda Pharmaceutical THIAZOLOPYRIMIDINE DERIVATIVE
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
ITMI20041231A1 (it) 2004-06-18 2004-09-18 Pharmeste Srl Antagonisti del recettore dei vanilloidi trpv1
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
FR2874015B1 (fr) 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006044762A2 (en) 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
JP4932730B2 (ja) 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
US7725934B2 (en) 2004-12-07 2010-05-25 Cisco Technology, Inc. Network and application attack protection based on application layer message inspection
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
CN101232885A (zh) 2005-01-25 2008-07-30 神经能质公司 经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物
JP2008540633A (ja) 2005-05-18 2008-11-20 ファイザー・リミテッド バソプレッシン拮抗薬としての１，２，４−トリアゾール誘導体
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US20070032473A1 (en) 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
KR20080097382A (ko) 2005-07-21 2008-11-05 뉴사우스 이노베이션즈 피티와이 리미티드 암의 치료 방법
ATE539753T1 (de) 2005-08-04 2012-01-15 Janssen Pharmaceutica Nv Pyrimidin-verbindungen als serotonin-rezeptor- modulatoren
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP1912639A4 (en) * 2005-08-08 2011-10-12 Janssen Pharmaceutica Nv Thiazolopyrimidine KINASE INHIBITORS
WO2007047798A1 (en) 2005-10-21 2007-04-26 Sensis Corporation Method and apparatus for providing secure access control for protected information
BRPI0618900A2 (pt) 2005-11-22 2011-09-27 Smithkline Beecham Corp compostos calcilìticos
JP4678685B2 (ja) 2005-12-26 2011-04-27 株式会社吉野工業所 エアゾール式液噴出器
DE102005062987A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20070155747A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
BRPI0706610A2 (pt) 2006-01-18 2011-04-05 Siena Biotech Spa moduladores de receptores alfa 7 nicotìnico acetilcolina e usos terapêuticos destes
EP1818330A1 (de) 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
AU2007225273A1 (en) 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
BRPI0709035A2 (pt) 2006-03-21 2011-06-21 Schering Corp compostos de piridina substituìda heterocìclica com atividade antagonista de cxcr3
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP5167250B2 (ja) 2006-05-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
ATE481409T1 (de) * 2006-05-18 2010-10-15 Hoffmann La Roche Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
TWI367112B (en) 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
US20080004286A1 (en) 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
WO2008005303A2 (en) 2006-06-30 2008-01-10 Janssen Pharmaceutica N.V. Thiazolopyrimidine modulators of trpv1
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
WO2008024139A2 (en) 2006-08-18 2008-02-28 N.V. Organon Inhibitors of fatty acid amide hydrolase
CA2661223A1 (en) 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-aminoquinazoline derivatives and methods of use thereof
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
WO2009079000A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1

Also Published As

Publication number Publication date
EP2224929B1 (en) 2016-05-04
JP5562865B2 (ja) 2014-07-30
UY31540A1 (es) 2009-07-17
AR069777A1 (es) 2010-02-17
WO2009078999A1 (en) 2009-06-25
JP2011506608A (ja) 2011-03-03
US8637527B2 (en) 2014-01-28
US8288397B2 (en) 2012-10-16
US20090156599A1 (en) 2009-06-18
PE20091102A1 (es) 2009-07-25
EP2224929A1 (en) 2010-09-08
US20160376291A1 (en) 2016-12-29
EP2224929A4 (en) 2011-08-03
US9440978B2 (en) 2016-09-13
US20140107098A1 (en) 2014-04-17
US20130005687A1 (en) 2013-01-03
PA8808201A1 (es) 2010-05-26
CL2008003749A1 (es) 2010-01-15

Similar Documents

Publication Publication Date Title
WO2008005303A3 (en) Thiazolopyrimidine modulators of trpv1
TW200942549A (en) Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
WO2006124748A3 (en) Multicyclic compounds and methods of their use
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MY144970A (en) Heterocyclic compounds
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009008425A (es) Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9.
WO2008100618A3 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2008100621A3 (en) Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2008100620A3 (en) Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders